What the business is, and whether it's a good one at a fair price.
The company operates a pharmaceutical business that generated Rs. 25.1936 crore from its named Pharma Business segment in FY26, up from Rs. 20.861 crore in FY25, against total FY26 revenue of Rs. 132.3062 crore. In June 2026, it signed an agreement with GMBU e.V., a research organisation in Halle (Saale), Germany, to scale up commercial production of Astaxanthin, a natural antioxidant pigment used in nutraceuticals and aquaculture, at its research facilities in Hyderabad, after successful pilot-scale work. The company is funding this expansion through preferential share issues: 12 lakh shares were allotted to 18 non-promoter investors at Rs. 57 each, raising Rs. 6.84 crore, alongside 33.75 lakh warrants converted by promoter-group entities at Rs. 20 each, raising Rs. 5.06 crore. The non-promoter issue proceeds are earmarked for technology transfer from GMBU Germany, a land lease deposit at Siddipet, land development, consumables, pre-operative expenses, and quality control equipment, with deployment targeted before September 30, 2026. EBIT from the Pharma Business in FY26 was Rs. 1.2329 crore, with total net profit of Rs. 2.5566 crore and an EBITDA margin of 2.6495%.
Measured from the filed financials, judged against its Healthcare Services peers · as of FY21 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from NOVELIX PHARMACEUTICALS LIMITE's filed financials and exchange disclosures
NOVELIX PHARMACEUTICALS LIMITE is a Healthcare Services company listed on BSE.
No. Over the trailing twelve months NOVELIX PHARMACEUTICALS LIMITE reported a net loss of ₹1 Cr on revenue of ₹6 Cr.
Not in the latest reported year — NOVELIX PHARMACEUTICALS LIMITE's dividend payout for FY21 was nil.
Effectively yes. It holds ₹3 Cr more cash than debt. Debt stands at 0.00× equity.
On a typical session NOVELIX PHARMACEUTICALS LIMITE moves 2.49% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by NOVELIX PHARMACEUTICALS LIMITE appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
